TriNetX says its real-world evidence (RWE) platform successfully leverages real-world data to generate real-world evidence to mirror results produced by randomized clinical trials (RCTs).
According to a press release, TriNetX’s study was published in the World Journal of Diabetes. The results replicated RCT results validating cardiovascular benefits of sodium-glucose co-transported-2 inhibitors in treatment of individuals with diabetes.
“The results showed that this type of analysis using real-world data could replicate the results coming from much more complex and costly studies,” TriNetX Chief Medical Officert Manfred Stapff, who led the study, said in a statement. “The study validates our methods and the quality of data in our network.”
Stapff says the study shows TriNetX is “perfectly positioned” to utilize the Food and Drug Administration’s recent framework on real-world evidence in drug development.